US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2024-0163 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Nipun Atreja und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb Company, NJ, USA. Hauptthemen laut MEDLINE: Pyrazoles, Atrial Fibrillation, Cost-Benefit Analysis, Dabigatran. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Warfarin and direct-acting oral anticoagulants (DOACs) are widely prescribed to patients with nonvalvular atrial fibrillation (NVAF) to reduce risk of stroke and systemic embolism (SE). This study aimed to assess the cost–effectiveness of apixaban compared with warfarin, dabigatran and rivaroxaban, for patients with NVAF from a US healthcare payer (Medicare) perspective.
Methods
A cohort-level Markov model was developed based on a previously published model, for the US setting, factoring in anticipated price decreases due to market entry of generic drugs. Two retrospective cohort studies in US Medicare patients provided inputs to quantify clinical events in the base case setting and in a scenario analysis. For this study, equal value of life-years (evLYs) and health years in total (HYT) were used. Cost–effectiveness was assessed based on a willingness-to-pay threshold of $100,000 per evLY gained (evLYG) or HYT gained (HYTG).
Results
Apixaban treatment was associated with gains of 2.23, 1.08 and 1.72 evLYs and 2.26, 1.08 and 1.73 HYTs, compared with warfarin, dabigatran and rivaroxaban, respectively. In the base case analysis from a Medicare perspective, apixaban was cost-effective (i.e., value for money) compared with warfarin, dabigatran and rivaroxaban, with corresponding incremental cost–effectiveness ratio (ICER) per evLYG (and HYTG) of $10,501 ($10,350), $7809 ($7769) and $758 ($768), respectively. When a societal perspective was included, and in a scenario analysis using US Medicare data from the Ray et al. study to quantify treatment effects, apixaban dominated rivaroxaban (i.e., less expensive and more effective) in terms of ICER per evLYG (and HYTG).
Conclusion
Using dynamic pricing assumptions, treatment with apixaban compared with warfarin, dabigatran and rivaroxaban was associated with incremental evLYs and HYT and represents a cost-effective treatment option in patients with NVAF, from a US healthcare payer (Medicare) perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb Company, NJ, USA.
- Bristol Myers Squibb Company, Stockholm, Sweden.
- Pfizer Ltd., Tadworth, UK.
- Health Economics & Outcomes Research Ltd., Cardiff, UK.
- Pfizer Inc., NY, USA.
Zitieren
APA
Atreja, N., Johannesen, K., Subash, R., Bektur, C., Hagan, M., Hines, D. M., Dunnett, I., & Stawowczyk, E. (2025). US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0163
Vancouver
Atreja N, Johannesen K, Subash R, Bektur C, Hagan M, Hines DM, et al. US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0163
BibTeX
@article{Atreja2025,
author = {Atreja, Nipun and Johannesen, Kasper and Subash, Rupesh and Bektur, Carina and Hagan, Melissa and Hines, Dionne M and Dunnett, Iulia and Stawowczyk, Ewa},
title = {US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2024-0163}
}
EUVIMED